Tegaserod: Long-Term Treatment for Irritable Bowel Syndrome Patients with Constipation in Primary Care

Digestion ◽  
2005 ◽  
Vol 71 (4) ◽  
pp. 238-244 ◽  
Author(s):  
Peter Layer ◽  
Jutta Keller ◽  
Stefan Mueller-Lissner ◽  
Peter Rüegg ◽  
Helena Loeffler
Keyword(s):  
Primary Care ◽  
Irritable Bowel Syndrome ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Irritable Bowel

Long-term treatment with probiotics in primary care patients with irritable bowel syndrome – a randomised, double-blind, placebo controlled trial

2013 ◽  
Vol 48 (10) ◽  
pp. 1127-1135 ◽  
Author(s):  
Luise Mølenberg Begtrup ◽  
Ove B Schaffalitzky de Muckadell ◽  
Jens Kjeldsen ◽  
René dePont Christensen ◽  
Dorte Ejg Jarbøl
Keyword(s):  
Primary Care ◽  
Irritable Bowel Syndrome ◽  
Controlled Trial ◽  
Term Treatment ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment ◽  
Primary Care Patients ◽  
Irritable Bowel

scholarly journals Benefits from Long-Term Treatment in Irritable Bowel Syndrome

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Stefano Evangelista
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Term Treatment ◽  
Short Course ◽  
Long Term Treatment ◽  
Cyclic Treatment ◽  
Stopping Treatment ◽  
Irritable Bowel ◽  
Additional Value

It is known that irritable bowel syndrome (IBS) is a chronic disease of cyclic nature characterized by recurrent symptoms. IBS patients should receive, as initial therapeutic approach a short course of treatment which, if effective, has the additional value of confirming the diagnosis. Long-term treatment should be reserved to diagnosed IBS patients with recurrent symptoms. Clinical trials with stabilized therapies and new active treatments showed an improvement of the symptoms over placebo that is often time-dependent but with high relapse rates (around 40%–50% when stopping treatment). Relapse is not always immediate after stopping treatment and the recent data from OBIS trial with otilonium bromide or with psychotherapy, showed that due to different chemico-physical characteristics of the drugs or the psychosomatic impact to the disease not all treatment gave the same relapsing rate if compared to placebo. Results of IBS clinical trials with different therapies tailored to the patient needs indicate that a cyclic treatment therapy is advisable to counteract the nature of the disease.

Orlistat in the Long-term Treatment of Obesity in Primary Care Settings.

2001 ◽  
Vol 21 (1) ◽  
pp. 53
Author(s):  
J Hauptman ◽  
C Lucas ◽  
M N Boldrin ◽  
H Collins ◽  
K R Segal
Keyword(s):  
Primary Care ◽  
Term Treatment ◽  
Primary Care Settings ◽  
Long Term Treatment ◽  
Treatment Of Obesity

scholarly journals Quality improvement for depression enhances long-term treatment knowledge for primary care clinicians

2000 ◽  
Vol 15 (12) ◽  
pp. 868-877 ◽  
Author(s):  
Lisa S. Meredith ◽  
Maga Jackson-Triche ◽  
Naihua Duan ◽  
Lisa V. Rubenstein ◽  
Patti Camp ◽  
...  
Keyword(s):  
Primary Care ◽  
Quality Improvement ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Treatment Knowledge ◽  
Primary Care Clinicians
Sign in / Sign up

Export Citation Format

Share Document